Both of the DVS Sciences™ brands of CyTOFand MAXPAR technology are covered by company patents.
DVS Sciences has created the commercial mass cytometry market by integrating two technologies that are not commonly thought of as compatible: flow cytometry and mass spectrometry.
Mass cytometry allows for the measurement of up to 100 biomarkers in individual cells at high speed.
The company incubated the technology at the University of Toronto and commercially launched its CyTOF - MAXPAR platform in November of 2009. It is currently in use by customers in Canada, the U.S., and Asia.
First customers include: Baylor College of Medicine, the Broad Institute, Cold Spring Harbor Laboratory, the US Department of Energy Joint Genome Institute, the Genome Center at Washington University, Monsanto, the National Cancer Institute/SAIC-Frederick, the National Center for Genome Resources, the Ontario Institute for Cancer Research, Stanford University, and the Wellcome Trust Sanger Institute.
Published a number of peer-reviewed articles in journals including Science, Nature and Nature Methods highlighting the power and potential applications of the SMRT platform.
Named a World Economic 2010 Technology Pioneer.
Ranked #1 Venture-backed company in US in 2010 by the Wall Street Journal.
The World Economic Forum (WEF) recognized Corventis as a “Technology Pioneer 2010” for the company’s work in developing innovative wireless cardiovascular solutions.
The American Telemedicine Association (ATA) awarded Corventis the President’s Innovation Award for 2010.
Corventis completed a 542 patient clinical trial - Multi-Sensor Monitoring in Congestive Heart Failure (MUSIC) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients).
Corventis received 510(k) clearance from the US Food and Drug Administration (FDA) and also received CE Mark to market its NUVANTTM Mobile Cardiac Telemetry (MCT) System for the detection of non-lethal arrhythmias.